HBAN
48
3
EIX
66
-3
FTI
78
9
A
46
3
UA
24
-9
AN
55
6
ORLY
60
-4
CMA
64
5
EQT
50
6
KO
47
-5
VRSN
55
5
SHW
73
2
FCX
58
5
XEL
62
-3
MET
54
3
WFC
61
3
HRB
73
3
HAS
57
2
HES
62
3
ADT
23
-10
HBAN
48
3
EIX
66
-3
FTI
78
9
A
46
3
UA
24
-9
AN
55
6
ORLY
60
-4
CMA
64
5
EQT
50
6
KO
47
-5
VRSN
55
5
SHW
73
2
FCX
58
5
XEL
62
-3
MET
54
3
WFC
61
3
HRB
73
3
HAS
57
2
HES
62
3
ADT
23
-10
Financhill
Back

ProQR Therapeutics NV 10K Form

Sell
27

PRQR
ProQR Therapeutics NV

Last Price:
1.79
Seasonality Move:
-2.94%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PRQR News And Ratings

See the #1 stock for the next 7 days that we like better than PRQR

PRQR Financial Statistics

Sales & Book Value

Annual Sales: $7.05M
Cash Flow: $-6.87M
Price / Cash Flow: 0
Annual Sales: $0.43
Price / Book: 4.15

Profitability

EPS (TTM): -0.28170
Net Income (TTM): $-23.34M
Gross Margin: $0
Return on Equity: -52.19%
Return on Assets: -16.12%

ProQR Therapeutics NV Earnings Forecast

Key ProQR Therapeutics NV Financial Ratios

  • The Selling, General & Administrative Expenses for PRQR have been equal to 249.25% of Gross Profit Margin.
  • The Research & Development expenses have been 386.06% of Revenue.
  • The Interest Expense is -4.28% of Operating Income.
  • The Net Earning history of PRQR is -431.67% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 5 years.

ProQR Therapeutics NV Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PRQR
CUSIP: N71542
Website: proqr.com

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 2.73
Quick Ratio: 2.7

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PRQR Technical Analysis vs Fundamental Analysis

Sell
27
ProQR Therapeutics NV (PRQR) is a Sell

Is ProQR Therapeutics NV a Buy or a Sell?